System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Marie-Delphine Lanic is an expert in Hematology at Centre Henri Becquerel (France). Marie-Delphine Lanic has authored 25 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 105 (community average: 125). How the SLR is computed.

LeadR Profile

Marie-Delphine Lanic Centre Henri Becquerel France
105 ScienceLeadR Reputation 105

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Surgery - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2019 - 2026
Source: PubMed

Institute for Research and Innovation in Biomedicine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 25

Citations

Citations: 166 1st author: 5 Last author: 0 Unique author: 0

Main journals

Am J Surg Pathol 4
Lab Invest 4
Blood 3
Ann Pathol 1
BMC Bioinformatics 1

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.
PMID 42386908 — cells, lymphoma, b-cell, lymphoma, leukemia, ligands, b-lymphocytes		Leukemia20260
Low-Grade Nasopharyngeal Papillary Adenocarcinoma: Toward a Better Molecular, Epigenetic, and Clinicopathological Understanding With Ontological Perspective.
PMID 42012880 — genes, nasopharynx, neoplasms, adenocarcinoma, adenocarcinoma, papillary, pathology, surgical		Am J Surg Pathol20260
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.
PMID 41979332 — cells, circulating tumor dna, lymphoma, b-cell, lymphoma, neoplasms, predictive value of tests, therapeutics, dna, b-lymphocytes		Blood Adv20260
Detection of Cancer-Associated Gene Fusion by Ligation-Dependent RT-PCR.
PMID 40699420 — genes, polymerase chain reaction, neoplasms, gene fusion, ligation, reverse transcriptase polymerase chain reaction		Methods Mol Biol20250
1131 Molecular Diversity of Clear Cell Carcinomas and Clear Cell Odontogenic Carcinomas Beyond the FET Genes : a morphological and molecular study of 47 tumors
OpenAlex W4408796779 — cells, genes, neoplasms, genes, vif		Lab Invest20250

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 1
Phase 2 1

By status:

Active not recruiting 1
Terminated 1

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone (CHOP) in Circulating Tumor (ct)DNA High Risk Patients With Untreated Diffuse Large B Cell Lymphoma
NCT04980222 — cytokines, cells, body surface area, prednisolone, safety, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, neoplasms, cytokine release syndrome, rituximab, vincristine, therapeutics, b-lymphocytes		Phase 2Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS